🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 10813929

    Treating cancer with ATR inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10813909

    Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer

    The Regents of the University of California · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10813952

    NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10815455

    Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1

    Vaximm AG · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10815484

    Compositions and methods for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10806730

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10799475

    Substituted phenyl aziridine precursor analogs for inhibiting androgen-independent prostate cancer cell growth

    Northwestern University · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10799604

    Biopolymer-nanoparticle composite implant for tumor cell tracking

    Northwestern University · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10799584

    Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10792274

    Dehydroacetic acid (DHAA) and derivative for uses in treating cancer

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10786501

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10787413

    Derivatives of curcuminoids and use thereof as an anticancer agent

    China Medical University · Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10786545

    Use of peptides that block metadherin-SND1 interaction as treatment for cancer

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10780076

    Inhibition of cancer cell motility

    Northwestern University · Granted Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10780093

    Methods of treating brain tumors using combination therapy

    Agios Pharmaceuticals, Inc. · Granted Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10772913

    Administration of kynurenine depleting enzymes for tumor therapy

    The Board of Regents of the University of Texas System · Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10772862

    Lipid scavenging in Ras cancers

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10768167

    Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer

    UNIVERSITÄTSKLINIKUM REGENSBURG · Granted Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10765745

    Multifunctional nanoparticle systems and methods for cancer diagnosis and combination therapy

    The Board of Regents of the University of Texas System · Granted Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10758613

    Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10759905

    Biodegradable amphiphilic polymer, polymeric vesicles prepared therefrom, and application of biodegradable amphiphilic polymer in preparation of medicines for targeted therapy of lung cancer

    BrightGene Bio-Medical Technology Co., Ltd. · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10758632

    NIR-conjugated tumor-specific antibodies and uses thereof

    The Regents of the University of California · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10758614

    Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10758526

    Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10751332

    Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

    Asana BioSciences, LLC · Granted Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10745701

    Methods of identifying and treating poor-prognosis cancers

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10744116

    Detection and treatment of anti-PD-1 therapy resistant metastatic melanomas

    The Regents of the University of California · Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10736919

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10736964

    Immunomagnetic nanocapsule and kit for treating cancer

    China Medical University · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10737995

    Nuclear receptor modulators and their use for the treatment and prevention of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10729725

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10722523

    Chemoimmunotherapy for epithelial cancer

    The Regents of the University of California · Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10722537

    Activation of resident memory T cells for cancer immunotherapy

    Regents of the University of Minnesota · Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10716809

    Methods of producing enriched populations of tumor reactive T cells from peripheral blood

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10711312

    Methods for immunotherapy-based treatment and assessment of cancer

    The Regents of the University of California · Granted Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10703746

    Mutant IDH1 inhibitors useful for treating cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10703735

    4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer

    Lead Discovery Center GmbH · Granted Tue Jul 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10695372

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10688181

    Cancer treatment combinations

    The Regents of the University of California · Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10689392

    Anti-cancer compounds targeting ral GTPases and methods of using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10689443

    Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer

    PRECISION BIOLOGICS, INC. · Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10682388

    Targeting of PELP1 in cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10683347

    Treatment of cancer using anti-TGF-β and anti-PD-1 antibodies

    The Regents of the University of California · Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10682339

    Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same

    The Board of Regents of the University of Texas System · Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10676480

    Anti-cancer compounds targeting Ral GTPases and methods of using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10675304

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10677801

    Diagnosis and treatment of breast cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10675267

    Methods for detection and eradication of myeloid leukemia stem cells

    The Regents of the University of California · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.